A Comparative, Randomized, Double blind, Multicentric, Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Besifloxacin ophthalmic suspension 0.6% Vs Moxifloxacin ophthalmic solution 0.5% in patients with Bacterial conjunctivitis.

Trial Profile

A Comparative, Randomized, Double blind, Multicentric, Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Besifloxacin ophthalmic suspension 0.6% Vs Moxifloxacin ophthalmic solution 0.5% in patients with Bacterial conjunctivitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs Besifloxacin (Primary) ; Moxifloxacin
  • Indications Bacterial infections; Infectious conjunctivitis
  • Focus Therapeutic Use
  • Sponsors Ajanta Pharma
  • Most Recent Events

    • 04 Sep 2010 Status changed from active, no longer recruiting to completed as reported by Clinical Trials Registry - India record.
    • 11 Aug 2010 Status changed from not yet recruiting to active, no longer recruiting as reported by Clinical Trials Registry - India record.
    • 14 Apr 2010 Planned initiation date changed from 12 Apr 2010 to 26 Apr 2010 as reported by Clinical Trials Registry - India record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top